6 completed. 6 Phase 3, 3 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 6 | Completed 6 |
| Phase 2 | 3 | Completed 3 |
Follow Hyperplasia: new trials by email Literature Review of Hyperplasia trials Research Report on Hyperplasia
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study to Treat Patients Who Have Signs and Symptoms of Benign Prostatic Hyperplasia (BPH) With Tadalafil Daily Placebo, tadalafil - Benign Prostatic Hyperplasia | Phase 3 | Completed | Eli Lilly and Company | 325 | 2009-01-01 | 2010-11-17 |
| Complementary and Alternative Medicine for Urological Symptoms(CAMUS) Saw Palmetto - first 24 weeks, Placebo - first 24 weeks, Saw Palmetto - weeks 24 - 48 - Urological | Phase 3 | Completed | University of Alabama at Birmingham | 369 | 2008-02-01 | 2012-10-12 |
| Chemoprevention Trial in Familial Adenomatous Polyposis (FAP) Coli Using EPA Eicosapentanoic Acid (EPA), Endoscopy, Biopsies taken - Familial Adenomatous Polyposis Coli, FAP | Phase 2 / Phase 3 | Completed | S.L.A. Pharma AG | 58 | 2006-11-01 | 2014-08-22 |
| Effect of 2 Doses of EPA on Apoptosis and Cell Proliferation on Colon Mucosa Eicosapentaenoic Acid (EPA), Endoscopy, Biopsies taken - Adenomatous Polyps | Phase 2 / Phase 3 | Completed | S.L.A. Pharma AG | 120 | 2006-10-01 | 2008-10-17 |
| Prevention of Autogenous Vein Graft Failure in Peripheral Artery Bypass Procedures CGT003 (E2F Duplex Decoy) - Peripheral Vascular Diseases, Arterial Occlusive Diseases | Phase 2 / Phase 3 | Completed | Anesiva, Inc. | 1400 | 2001-11-01 | 2005-07-15 |
| A Study of the Effects of Pegvisomant on Growth Hormone Excess in McCune-Albright Syndrome Pegvisomant - McCune Albright Syndrome, Polyostotic Fibrous Dysplasia | Phase 3 | Completed | National Institute of Dental and Craniofacial Research (NIDCR) | 10 | 2001-06-01 | 2008-03-04 |
Polyps (2) · Acromegaly (1) · Adenoma (1) · Adenomatous Polyposis Coli (1) · Adenomatous Polyps (1) · Arterial Occlusive Diseases (1) · Atherosclerosis (1) · Fibrous Dysplasia, Polyostotic (1) · Genital Diseases, Male (1) · Graft Occlusion, Vascular (1) · Ischemia (1) · Peripheral Vascular Diseases (1) · Prostatic Diseases (1) · Prostatic Hyperplasia (1)
Pathologic Processes (6) · Pathological Conditions, Signs and Symptoms (6) · Neoplasms (3) · Neoplasms by Histologic Type (3) · Neoplasms, Glandular and Epithelial (3) · Adenoma (2) · Pathological Conditions, Anatomical (2) · Adenomatous Polyps (1) · Arteriosclerosis (1) · Bone Diseases (1) · Bone Diseases, Developmental (1) · Bone Diseases, Endocrine (1) · Brain Diseases (1) · Cardiovascular Diseases (1) · Central Nervous System Diseases (1)
Eicosapentaenoic Acid (2) · Endoscopy (2) · Clinical Chemistry Tests (1) · Colonoscopy (1) · Restraint, Physical (1) · Tadalafil (1) · pegvisomant (1)
S.L.A. Pharma AG (2) · Anesiva, Inc. (1) · Eli Lilly and Company (1) · National Institute of Dental and Craniofacial Research (NIDCR) (1) · University of Alabama at Birmingham (1)
United States (4) · Canada (2) · Italy (2) · United Kingdom (2) · Argentina (1) · Germany (1) · Mexico (1)
Nicholas J West, MB BS FRCS (2) · Alan Cantor, PhD (1) · Michael Barry, MD (1) · Todd Lorenz, M.D. (1)
PMID 20348368, PMID 21497839, PMID 21741692, PMID 21871706, PMID 21954478, PMID 23083656, PMID 26299520
U01DK063788 (1)